Chapter 27: Antidepressants

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive, where we take the really heavy clinical concepts from your medical prep and translate them into a practical framework.

Right, for all you clinicians, board preppers, and students out there, consider this your specialized one -on -one tutoring session.

Exactly.

We're doing a deep dive into the source material of Chapter 27 of Len's Pharmacotherapeutics.

And our mission today is mastering the pharmacotherapy of major depression.

We're going to build a clinical decision -making framework going straight from the underlying

pathophysiology right through to safe patient -centered outcomes.

When most people think about treating depression, they imagine refilling a car's empty gas tank.

Right, the old gas tank analogy.

Yeah, like you just take a pill to top off your serotonin or norepinephrine, and boom, the engine runs smoothly again.

But treating depression isn't about topping off a tank at all, is it?

No.

Well, it fundamentally changes how you approach prescribing when you abandon that idea.

I mean, the idea you just described is the monamine deficiency hypothesis.

Which is still taught, right?

It is, yeah.

It's taught because it gives us a good starting point.

It posits that depression is caused by a functional deficiency of monoamine neurotransmitters, mostly serotonin and norepinephrine.

Okay, but why is that too simplistic?

Because if it were just about replacing missing chemicals, a patient would feel better the literal moment a drug like an SSRI hits their bloodstream.

Which simply doesn't happen.

Exactly.

The biochemical effect of flooding the synapse happens within hours, but the patient usually doesn't report feeling any actual relief from their depression for

weeks.

So it's less like refilling a gas tank, and more like, I don't know, physical therapy for a frozen shoulder.

Oh, that's a great way to look at it.

The medication just gets the neurotransmitters moving, but the real healing is the structural cellular adaptation.

And that takes sustained effort.

Right.

The sustained reuptake blockade eventually triggers long -term adaptive cellular changes in the brain.

We're talking about changes in receptor sensitivity and even the promotion of neurogenesis.

Wow.

So literally growing new neurons.

Yeah.

And that cellular adaptation is what actually brings clinical relief.

So understanding this delayed time course is just the absolute bedrock of patient education.

So before you even write a prescription, you have to establish exactly what you're treating.

Right.

That means drawing a hard line between normal human grief and a major depressive episode.

Which is a really crucial clinical distinction for anyone listening to make.

For sure.

Because, I mean, grief is a completely appropriate proportional reaction to a major life stressor.

It fluctuates, and it usually resolves spontaneously.

Right.

Whereas major depression is a systemic illness.

Exactly.

To diagnose it, the principal symptoms, like a persistently depressed mood and a profound loss of pleasure in nearly all activities, have to be present most of the day, nearly every day.

For at least two weeks, right?

Right.

A minimum of two weeks.

And once you establish that diagnosis, the therapeutic goal is full remission.

We aren't just trying to take the edge off.

No, we want full remission.

But realistically, only about 30 % of patients actually achieve full remission with the first drug they try.

30%.

That's surprisingly low.

It is.

Though another 20 to 30 % will see at least a 50 % reduction in symptom severity.

And keep in mind, for mild to moderate depression, therapy and drugs are equally effective.

But for severe depression, you really need a combination of both.

Okay.

So if you're the clinician managing that drug therapy,

there is a massive safety baseline you have to establish on day one.

Oh, absolutely.

I'm talking about the black box warning that is slapped on literally every single antidepressant on the market.

Right.

The increased risk of suicide.

Which seems so counterintuitive, like a drug meant to treat depression causing suicide.

The irony is dark, but it's actually pharmacologically sound.

This risk is highest very early in treatment, and it primarily affects children, adolescents,

and young adults under the age of 25.

Wait, so let me get this straight.

If the drug takes three or four weeks to actually lift their mood, but it floods their synapses with activating neurotransmitters on day one.

Yes, you're tracking exactly.

Does that mean they suddenly get this burst of physical energy to carry out a suicidal plan before their psychological despair has actually lifted?

That is the exact mechanism driving the warning.

The psychomotor retardation lifts before the cognitive despair does.

You're giving a deeply depressed patient the sudden energetic means to act.

Wow.

So how do you manage that practically in a clinic?

It requires an intensive monitoring timeline.

You don't just hand a young adult a prescription and say, see you in three months.

You or a trained caregiver must meet with the patient weekly during the first four weeks of treatment.

Weekly?

That's a lot.

It is, but then it's bi -weekly for the next four weeks and then monthly visits.

And the patient's family has to be brought into the loop too.

They need to be monitoring them daily.

Yes, daily for signs of clinical decline, sudden agitation, panic attacks, extreme irritability or hostility.

Those are massive red flags.

And setting expectations about that timeline probably prevents a lot of premature treatment abandonment, I'd imagine.

Oh, 100%.

You have to educate the patient that initial responses take one to three weeks.

And maximal responses can take up to 12 weeks.

So you can't just quit after two weeks?

No, a therapeutic trial isn't considered a failure until a drug has been taken as prescribed for at least one solid month without success.

Okay, so let's get into the actual drugs.

Because safety and tolerability drive rational drug selection, clinicians almost always start with the safest, best tolerated options.

Right, which brings us to our first line defenders,

the selective serotonin reuptake inhibitors, or SSRIs, and the serotonin or pinephrine reuptake inhibitors, the SNRIs.

Let's look at the SSRI prototype from the serotonin, also known as 5 -HT.

By blocking the reuptake pump on the presynaptic neuron, it traps serotonin in the synaptic cleft.

Forcing increased activation of the postsynaptic receptors.

Exactly.

But the pharmacokinetics of fluoxetine are wild.

I was reading this and it drastically alters clinical decision -making.

It really does because fluoxetine itself has a half -life of two days.

But it undergoes extensive hepatic metabolism in the liver to an active metabolite called norefluoxetine.

And norefluoxetine is a half -life of seven whole days, right?

Yes, seven days.

So the effect of half -life becomes incredibly prolonged.

It takes about four weeks of daily dosing just to reach steady -state plasma drug levels.

And conversely, it takes four full weeks for the drug to completely wash out of the patient's system after they stop.

Exactly.

So if a patient's depression isn't responding to fluoxetine, and you decide to switch them to a completely different class of drug like, say, an MAOI, you can't just tell them to stop the SSRI on Friday and start the new drug on Monday.

Because you'd be stacking a new drug on top of a massive reserve of norefluoxetine still lingering in their tissues.

Right.

And the resulting drug interaction could literally be fatal.

You are required to wait a minimum of five weeks after stopping fluoxetine before you can safely initiate an MAOI.

Five weeks.

That is a huge clinical pearl for you guys listening.

So let's talk about the adverse effects of SSRIs.

They are safer than older drugs, but they definitely aren't side -effect free.

Definitely not.

Weight gain is a notorious adherence killer.

But the really prominent issue is sexual dysfunction.

Which occurs in nearly 70 % of patients, right?

Yeah, nearly 70 % of men and women taking fluoxetine.

Decreased libido, delayed orgasm, or complete anergasmia.

It just destroys patient compliance.

And patients are probably too embarrassed to bring it up.

Oh, all the time.

They won't report it unless you proactively ask them.

But there are management strategies.

Sometimes a simple dose reduction helps.

The text also mentioned drug holidays.

What are those?

Yeah.

So under strict provider guidance, a patient might skip their dose on Fridays and Saturdays.

That allows the drug concentration to dip just enough to permit normal sexual function over the weekend.

Or you can add a drug like bupropion to the regimen.

Right.

Because bupropion acts on entirely different pathways to reverse those sexual side effects.

Okay, we also need to talk about serotonin syndrome.

Because if a patient has too much seroenergic transmission in their brain stem and spinal cord,

they're in real danger.

What does that actually look like if they walk into an ER?

It's a rapid onset medical emergency.

It usually begins anywhere from 2 to 72 hours after treatment onset.

And there's a specific triad of symptoms, right?

Yes.

The triad involves altered mental status.

So profound confusion, agitation, disorientation, autonomic instability, like excessive sweating and fever, and then neuromuscular abnormalities.

Like in coordination and hyperreflexia.

Exactly.

Myoclonus, hyperreflexia.

And the risk skyrockets if you accidentally combine an SSRI with an MAOI, which reinforces that strict five -week washout rule we just talked about.

Wait.

If fluoxetine takes five whole weeks to wash out of an adult system, I can't even imagine what that prolonged half -life does to a developing fetus if the patient is pregnant.

It's a major concern.

The risks late in pregnancy are very significant.

Using SSRIs in the third trimester exposes the newborn to neonatal abstinence syndrome.

So the baby goes through withdrawal.

Yeah.

The infant presents with irritability, abnormal crying, tremor, and respiratory distress.

Furthermore, there's a risk for persistent pulmonary hypertension of the newborn, or PPHN.

Oh, wow.

PPHM.

Because the elevated serotonin levels in the fetus cause constriction of the pulmonary vasculature, which compromises tissue oxygenation.

It carries a severe risk of cognitive delay, or even mortality.

Okay.

So that covers our serotonin -only approach.

Yeah.

But what happens to the clinical picture when we add norepinephrine to the mix with the SNRIs, like venlafaxine?

So venlafaxine blocks the re -uptake of both serotonin and norepinephrine.

The clinical efficacy is pretty similar to the SSRIs, but the side -effect profile shifts.

Because norepinephrine drives the sympathetic nervous system.

Exactly.

Because venlafaxine traps norepinephrine in the synapse, it can cause dose -related sustained diastolic hypertension.

Clinicians really must monitor baseline and ongoing blood pressure.

And I'd imagine the withdrawal syndrome for an SNRI is pretty brutal, considering you're dropping the levels of two major neurotransmitters at once.

It is intense.

Abrupt cessation of venlafaxine triggers this severe withdrawal cascade.

Patients experience severe anxiety, agitation, tremors, vertigo, tachycardia.

So you have to taper it.

Tapering slowly over two to four weeks is absolutely mandatory.

Let's pivot a bit.

Say your patient doesn't respond to those first -line agents,

or maybe they have a specific comorbidity like fibromyalgia or neuropathic pain.

Right.

Which our older drugs are actually great at managing.

Yeah.

So if SSRIs fail, we move to the second -line agents,

the tricyclic antidepressants or TCAs.

And the prototype here is Imurpromen.

So TCAs share the same core mechanism as the SNRIs.

They block the neuronal reuptake of norepinephrine and serotonin.

But their molecular structure makes them highly non -selective.

Which completely changes their safety profile.

Yeah.

I always think of TCAs as like a sloppy painter.

A sloppy painter.

I like that.

Yeah.

Imagine you hire a painter to paint your front door.

The front door represents the serotonin and norepinephrine reuptake pumps.

But this painter is sloppy.

They swing the brush wildly, getting paint on the windows, the brick, the porch light.

Right.

They hit things they weren't aiming for.

Exactly.

That's what TCAs do in the brain.

They don't just hit their intended targets.

They accidentally blockade a bunch of other cellular receptors they had no business touching.

That analogy perfectly captures the pharmacodynamics of Imurpromen.

TCAs cause direct blockade of histamine receptors in the brain, which leads to profound heavy sedation.

And they block muscarinic cholinergic receptors too.

Right.

Triggering widespread anticholinergic effects.

Severe dry mouth, blurred vision, photophobia, constipation, urinary hesitancy.

And they also block alpha -1 adrenergic receptors on blood vessels.

Which means when the patient stands up quickly, their blood vessels lack the adrenergic signal to constrict properly, right?

Exactly.

Their blood pressure drops and they experience orthostatic hypotension.

So you have to aggressively educate them to move slowly from sitting to standing.

But annoying side effects aren't really why TCAs are relegated to second line status, are they?

No.

It's the toxicity.

The lethal dose of a TCA is only eight times the average therapeutic dose.

Wow.

Just eight times.

That is a terrifyingly narrow therapeutic index.

It really is.

The primary cause of death in a TCA overdose is acute cardiac toxicity.

If we look at the specific cardiac pharmacology, TCAs physically slow down electrical conduction in the bundle of his.

And they block fast sodium channels, right?

Yes.

They block fast sodium channels in the cardiac myocytes.

And since a rapid influx of sodium is what triggers the cardiac action potential, blocking those channels severely prolongs depolarization.

Which widens the QRS complex on an ECG.

Exactly.

And that produces lethal ventricular dysrhythmias.

So to handle that massive risk clinically, you have to obtain a baseline ECG for all patients before starting a TCA.

And check it periodically.

Also, to prevent intentional suicide by overdose,

the clinical guideline is to prescribe only small amounts of the drug at a time.

Maybe just a one week supply.

And if a patient does overdose, what are the emergency interventions?

It involves gastric lavage, administering activated charcoal to bind the drug in the gut, and pushing intravenous sodium bicarbonate.

To overcome the sodium channel blockade and control the dysrhythmias.

Exactly.

Okay, so if the sloppy TCAs are too dangerous because of their cardiac risk, and a patient is still struggling with severe treatment resistant atypical depression,

what's next?

Clinicians are kind of pushed into a corner.

They are.

They have to pull out the monoamine oxidase inhibitors, MAOIs.

But everything I've ever read about MAOIs makes them sound like a massive dietary minefield.

The dietary restrictions are, without a doubt, the single biggest barrier to using them.

So, MAOIs cause irreversible inhibition of the monoamine oxidase enzyme.

Specifically, they block MAOA, which is the enzyme responsible for destroying rogue norepinephrine and serotonin in the brain, as well as MAOB.

And because this inhibition is irreversible, the patient's body has to synthesize entirely new MAO molecules from scratch once they stop taking the drug.

Right, meaning the effects persist for about two full weeks after the last dose.

But why does an enzyme inhibitor working in the brain dictate what a patient is allowed to eat for lunch?

It comes down to a really potent interaction with a dietary substance called tiramine.

If you map out the biochemistry of the human gut, you have large amounts of MAO functioning in your intestinal wall and your liver.

When you eat foods rich in tiramine like aged cheeses, cured or fermented meats, yeast extracts, or imported draft beers,

that intestinal and hepatic MAO acts as a defense mechanism.

It destroys the tiramine before it can reach your general circulation.

It's like a bouncer at the door of an exclusive club tossing out the troublemakers before they get inside.

That's a perfect way to picture it.

But the MAOI eliminates the bouncer.

It indiscriminately blocks the MAO in the gut and the liver, too.

So that dietary tiramine passes completely intact straight through the intestinal wall, survives the liver, and floods into the systemic bloodstream.

And once it's in the bloodstream?

It travels directly to peripheral sympathetic nerve terminals.

Remember, the MAOI has already prevented the breakdown of norepinephrine, leading to a massive accumulation of it within these nerve terminals.

So the tiramine gets in there and just forces it all out.

Exactly.

It physically displaces all that accumulated norepinephrine, dumping it massively into the synapse.

The result is systemic catastrophic vasoconstriction and intense overstimulation of the heart.

A full -blown hypertensive crisis.

The patient experiences a severe headache, tachycardia, palpitations, nausea, and faces an immediate risk of a stroke or even death.

Which is why strict adherence to a tiramine -free diet is an absolute non -negotiable prerequisite for this therapy.

You simply cannot prescribe an MAOI to a patient who lacks the cognitive capacity, housing stability, or willingness to follow these dietary restrictions.

And they also have to avoid all indirect acting sympathomimetics.

Yes.

Anything that promotes norepinephrine release.

So a patient taking an over -the -counter cold medicine containing ephedrine could trigger the exact same hypertensive crisis.

Wow.

Is there any way around the gut interaction?

Because demanding a patient give up aged cheese, cured meats, and cold medicine while they're already battling severe depression, that's a huge ask.

It is, but a major pharmacological breakthrough provided an alternative, transdermal seligelin.

Oh, an MAOI delivered via a skin patch.

Exactly.

At low doses, specifically 6 mg per 24 hours, the patch delivers the drug directly into the systemic circulation,

completely bypassing the gastrointestinal tract.

Oh, that's brilliant.

Therapeutic levels are achieved in the brain to treat the depression, but the MAOA in the intestinal wall and the liver is left totally intact.

The bouncer's back on duty at the gut level.

Exactly.

The intact hepatic MAO destroys the dietary tiramine, significantly lowering the risk of a hypertensive crisis without sacrificing the antidepressant effect in the brain.

Do they still have to avoid the cold medicine?

You still must instruct patients to avoid sympathomimetic drugs like ephedrine, yes, but the dietary freedom makes the transdermal route vastly superior for compliance.

That makes total sense.

So let's rewind a bit, though.

We've talked about this stepwise progression of failure, moving to heavier, more dangerous drugs.

Right.

But what if our patient is actually responding well to an SSRI?

Their mood is stable, but they're experiencing intolerable side effects,

like crushing fatigue or that 70 % sexual dysfunction rate.

This is exactly where atypical antidepressants shine, because we can use highly targeted drug selection to solve specific clinical puzzles.

OK.

Let's look at Bupropion.

So Bupropion is structurally unique.

It actually resembles amphetamine.

Because it acts much like a central nervous system stimulant, it generally causes weight loss rather than weight gain.

And it helps with the sexual side effects.

Crucially, yes.

Unlike the SSRIs, it enhances sexual desire and pleasure.

It is a brilliant clinical selection to add to a patient's regimen if they are struggling with SSRI -induced sexual dysfunction.

But because Bupropion acts like a stimulant, I'm assuming the catch involves overstimulation of the brain.

You'd be right.

The heart safety limit on Bupropion is that it significantly lowers the seizure threshold.

At extender -release doses greater than 450 mg per day, it produces seizures in nearly half a percent of patients.

So you have to strictly avoid prescribing it to anyone with a pre -existing elevated seizure risk.

Exactly.

Screening for a history of head trauma is a must.

But it also means screening for eating disorders like anorexia or bulimia.

Oh, because the severe electrolyte imbalances inherent in those conditions inherently increase seizure risk.

Right.

You also can't give it to patients undergoing sudden withdrawal from alcohol or benzodiazepines as their nervous systems are already highly irritable and seizure -prone.

Okay, wow.

So a side -effect profile that ruins one patient's quality of lice becomes a perfect targeted therapy for another.

Precisely.

And then we have the true outliers, like esketamine.

It is a completely different mechanism from the monoamine modulators.

Esketamine is an NMDA receptor antagonist administered via a nasal spray.

So it's not working on serotonin or norepinephrine at all?

Nope.

Instead, it works rapidly on glutamate, which is the brain's primary excitatory neurotransmitter.

By blocking NMDA receptors, it triggers a fast intracellular cascade that promotes rapid synaptogenesis.

Meaning it offers relief for treatment -resistant depression in hours rather than weeks.

Yes, hours.

But because it's a derivative of ketamine and it alters major excitatory pathways in the cortex, it heavily distorts sensory processing.

The dissociation must be intense.

The dissociation and sedation are very intense.

Patients report feeling detached from their own bodies or reality.

Because of the potential for psychological distress, misuse, and profound sedation, esketamine is strictly regulated under a REMES program.

A risk evaluation and mitigation strategy.

Exactly.

A patient cannot take this medication home.

It requires administration in a certified clinic, followed by a minimum of two hours of continuous in -office monitoring.

We have covered a tremendous amount of ground.

But we really need to apply this clinical framework to one of the most vulnerable populations in healthcare.

New mothers experiencing peripartum depression.

Yes.

The first clinical step here is distinguishing between the transient baby blues and true peripartum depression.

The baby blues are incredibly common, affecting up to 80 % of women.

They experience mild tearfulness, anxiety, and irritability, largely due to sudden hormonal shifts and sleep deprivation.

But it resolves spontaneously within 10 days.

No pharmacological treatment is indicated.

True peripartum depression, however, is a major depressive episode that begins during pregnancy or within four weeks of delivery.

Though clinically, I know we often monitor closely for up to three months postpartum.

Right.

Left untreated, it severely impairs maternal functioning and poses a documented threat to the infant's cognitive, emotional, and behavioral development.

Immediate intervention is absolutely required.

And the pathophysiology here goes way beyond monoanines, doesn't it?

It does.

It involves the precipitous drop in estrogen and progesterone after birth, which triggers a dangerous downregulation of GABA receptors.

And GABA normally acts as the brain's breaking system.

Exactly.

Without enough GABA signaling, the hypothalamic pituitary adrenal axis, or HPA axis, becomes hyperactive, driving severe anxiety and depression.

Which perfectly explains why the newest FDA -approved therapies for this don't target serotonin at all.

Right.

Rixanolone is an IV infusion restricted to clinical settings.

And Zirinolone is the first oral drug approved specifically for postpartum depression, taken as a short 14 -day course.

Both of these are neuroactive steroids that target GABA receptors directly, right?

Yes.

Restoring that inhibitory breaking system to calm the hyperactive HPA axis.

But if a clinician is utilizing traditional antidepressants for a new mother, the immediate concern shifts to the infant.

All of these drugs enter brush milk to some degree.

So rational drug selection requires knowing which ones accumulate in the baby.

Exactly.

Sertraline and peroxetine are generally considered safe.

Pharmacokinetic studies show extremely low levels transfer into the milk, and adverse reactions in infants are rare.

But fluoxetine is a completely different story.

If you've been tracking the pharmacology we discussed earlier, you probably already know why fluoxetine is distinctly unsafe for breastfeeding mothers.

Right.

The drug's incredibly long half -life is the culprit.

That two -day half -life for the parent drug and seven -day half -life for the active metabolite norefluoxetine means the newborn's immature liver simply cannot clear it.

So the drug accumulates rapidly in the nursing infant, reaching therapeutic plasma levels.

Which causes severe colic, irritability, and impaired weight gain in the baby.

It is so incredibly satisfying when the basic pharmacology directly answers a complex clinical dilemma like that.

It really is.

We started today by tearing down that simple gas tank analogy of depression.

We mapped out the first line SSRIs and SNRIs navigating half -lives and serotonin syndrome.

And we respected the narrow therapeutic index and cardiac risks of our sloppy painters, the TCAs.

Right.

Then we reasoned our way through the intense dietary blockades of the MAOIs to avoid hypertensive crises.

We used atypicals like bupropion and mirtazapine to turn side effects into targeted solutions.

And finally, we protected postpartum mothers and their infants by applying deep pharmacokinetic logic.

The depth of pharmacology required to prescribe safely is profound.

It is.

But I want to leave you with a final thought to mull over regarding neuroplasticity.

If it takes weeks of sustained chemical pressure from these drugs to force the brain to physically alter its own structure, grow new synapses, and change its receptor sensitivity, consider what that means about the sheer resilience of the human nervous system.

That's a great point.

We aren't just altering chemistry in a closed loop.

We are actively coaxing the brain to rebuild its own pathways in real time.

It's truly amazing.

The brain is a living, adapting network.

And knowing how to guide that adaptation is what makes you an exceptional provider.

Thank you for studying hard and for taking the time to master the why behind the what.

Straight from all of us here at the Last Minute Lecture team, thanks for joining us for this deep dive.

Keep pushing forward, and we'll catch you on the next one.